Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remifemin reacquisition

This article was originally published in The Tan Sheet

Executive Summary

Enzymatic Therapy acquires distribution rights for menopausal treatment product Remifemin from GlaxoSmithKline, according to a May 25 announcement. GSK will transfer rights for the product to the Green Bay, Wisc.-based firm when the transaction becomes effective June 20. Enzymatic Therapy says it will partner with German Remifemin manufacturer Shaper & Brummer to boost product distribution and market share. The firm distributed the hormone-free menopausal therapy between 1995 and 2000, prior to the product's entry to the mass market under GSK...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel